

Ayal A Aizer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6674064/publications.pdf>

Version: 2024-02-01

118
papers

5,594
citations

108046

37
h-index

97045

71
g-index

120
all docs

120
docs citations

120
times ranked

8553
citing authors

#	ARTICLE	IF	CITATIONS
1	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	0.6	83
2	Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: a population- and institutional-level analysis. <i>Neuro-Oncology Practice</i> , 2022, 9, 114-122.	1.0	1
3	Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. <i>Physics in Medicine and Biology</i> , 2022, 67, 065009.	1.6	2
4	Predictors of long-term survival among patients with brain metastases. <i>Neuro-Oncology</i> , 2022, , .	0.6	2
5	Trends in location of death for individuals with primary brain tumors in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1400-1401.	0.6	2
6	Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. <i>World Neurosurgery</i> , 2022, 162, e401-e415.	0.7	2
7	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. <i>Journal of Neuro-Oncology</i> , 2022, 157, 499-510.	1.4	2
8	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
9	Salvage brachytherapy for multiply recurrent metastatic brain tumors: A matched case analysis. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac039.	0.4	0
10	Population-based estimates of survival among elderly patients with brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 661-676.	0.6	25
11	Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. <i>European Radiology</i> , 2021, 31, 4114-4129.	2.3	22
12	Seizures Among Patients With Brain Metastases. <i>Neurology</i> , 2021, 96, .	1.5	12
13	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. <i>Medical Dosimetry</i> , 2021, 46, 21-28.	0.4	4
14	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. <i>Korean Journal of Radiology</i> , 2021, 22, 584.	1.5	12
15	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	2.8	4
16	Epidemiology of brain metastases and leptomeningeal disease. <i>Neuro-Oncology</i> , 2021, 23, 1447-1456.	0.6	123
17	Is radiation necrosis in radiated melanoma brain metastasis increasing because immunotherapy is contributing to this or are patients just living longer?. <i>Journal of Clinical Oncology</i> , 2021, 39, e21518-e21518.	0.8	0
18	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 569-580.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Surgical and Peri-Operative Considerations for Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 662943.	1.3	15
20	Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). <i>Radiotherapy and Oncology</i> , 2021, 160, 159-165.	0.3	67
21	Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318.	1.2	4
22	The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 1816-1817.	0.6	3
23	Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. <i>American Journal of Roentgenology</i> , 2021, 217, 1184-1193.	1.0	13
24	NEIM-04. PROSPECTIVE STUDY OF SCREENING MRI OF THE BRAIN IN PATIENTS WITH METASTATIC OR INFLAMMATORY BREAST CANCER. <i>Neuro-Oncology Advances</i> , 2021, 3, iv7-iv7.	0.4	0
25	Identification and Characterization of Leptomeningeal Metastases Using SPINE, A Web-Based Collaborative Platform. <i>Journal of Neuroimaging</i> , 2021, 31, 324-333.	1.0	3
26	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2020, 133, e804-e812.	0.7	4
27	Utility of claims data for identification of date of diagnosis of brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 575-576.	0.6	12
28	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2 ⁻ Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e232-e243.	1.1	29
29	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.4	0
30	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020, 126, 5274-5282.	2.0	19
31	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 1547-1548.	0.6	2
32	Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1972.	3.4	22
33	Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer. <i>Radiology</i> , 2020, 297, 419-427.	3.6	21
34	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	0.8	223
35	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. <i>World Neurosurgery</i> , 2020, 139, 226-231.	0.7	5
36	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1028.	3.4	122

#	ARTICLE	IF	CITATIONS
37	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 509-517.	1.4	7
38	Hospice Utilization in Elderly Patients With Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1251-1258.	3.0	7
39	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	0.6	27
40	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-16.	0.6	33
41	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	0.6	49
42	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.4	81
43	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	0.6	3
44	Bilateral occipital metastases: Visual deficits and management considerations. , 2020, 11, 428.		1
45	Alcohol Use Among Patients With Cancer and Survivors in the United States, 2000-2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 69-79.	2.3	29
46	Molecular Taxonomy of Meningioma. , 2020, 81, .		0
47	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	0.6	5
48	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii228-ii228.	0.6	0
49	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2020, 22, ii186-ii187.	0.6	0
50	NCOG-09. EFFICACY OF HER2-TARGETED ANTIBODY THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS. <i>Neuro-Oncology</i> , 2020, 22, ii131-ii131.	0.6	0
51	Prevalence of chronic pain among cancer survivors in the United States, 2010-2017. <i>Cancer</i> , 2019, 125, 4310-4318.	2.0	37
52	EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 32-38.	0.9	17
53	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 39-45.	0.9	26
54	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. <i>Acta Oncologica</i> , 2019, 58, 1275-1282.	0.8	50

#	ARTICLE	IF	CITATIONS
55	SURG-09. SURGICAL AND PERI-OPERATIVE CONSIDERATIONS FOR BRAIN METASTASES: A NATIONWIDE ANALYSIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i32-i32.	0.4	0
56	MLTI-12. TIMING OF SYSTEMIC THERAPY ADMINISTRATION RELATIVE TO STEREOTACTIC RADIOSURGERY AND DEVELOPMENT OF RADIATION NECROSIS IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i16-i17.	0.4	0
57	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. <i>JAMA Oncology</i> , 2019, 5, e191973.	3.4	12
58	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. <i>JAMA Network Open</i> , 2019, 2, e193759.	2.8	34
59	Survival and prognostic factors in surgically treated brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 143, 359-367.	1.4	35
60	Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. <i>JAMA Oncology</i> , 2019, 5, 703.	3.4	63
61	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	1.1	15
62	Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. <i>JAMA Oncology</i> , 2019, 5, 735.	3.4	44
63	A low percentage of metastases in deep brain and temporal lobe structures. <i>Neuro-Oncology</i> , 2019, 21, 640-647.	0.6	8
64	Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. <i>Cancer Medicine</i> , 2019, 8, 13-20.	1.3	55
65	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	1.4	13
66	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. <i>Translational Research</i> , 2019, 208, 63-72.	2.2	13
67	Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017. <i>JAMA Oncology</i> , 2019, 5, 426.	3.4	22
68	EPID-22. NEWLY-DIAGNOSED BRAIN TUMORS IN PEDIATRIC PATIENTS: EPIDEMIOLOGY IN THE UNITED STATES. <i>Neuro-Oncology</i> , 2019, 21, vi79-vi79.	0.6	0
69	EPID-21. THE NATIONAL SPECTRUM OF NEWLY-DIAGNOSED BRAIN TUMORS IN ADULT PATIENTS VARIES SIGNIFICANTLY BY PATIENT DEMOGRAPHICS. <i>Neuro-Oncology</i> , 2019, 21, vi79-vi79.	0.6	0
70	Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2019, 35, 73-80.	0.9	20
71	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.4	118
72	The Misclassification of Diffuse Gliomas: Rates and Outcomes. <i>Clinical Cancer Research</i> , 2019, 25, 2656-2663.	3.2	42

#	ARTICLE	IF	CITATIONS
73	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	0.7	17
74	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019, 5, 474-481.	1.6	44
75	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. <i>Cureus</i> , 2019, 11, e4726.	0.2	2
76	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	0.6	9
77	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.3	18
78	Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. <i>JAMA Oncology</i> , 2018, 4, 1123.	3.4	238
79	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018, 131, 517-523.	0.6	13
80	CMET-32. BILATERAL OCCIPITAL METASTASES: MANAGEMENT CONSIDERATIONS AND CORTICAL BLINDNESS. <i>Neuro-Oncology</i> , 2018, 20, vi60-vi61.	0.6	0
81	CMET-07. FRAILITY PREDICTS MORTALITY AFTER RESECTION OF BRAIN METASTASES. <i>Neuro-Oncology</i> , 2018, 20, vi55-vi55.	0.6	0
82	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1001.	3.4	44
83	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	1.6	60
84	Brain Metastases. <i>Neurologic Clinics</i> , 2018, 36, 557-577.	0.8	24
85	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.4	143
86	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	0.6	483
87	Whole brain radiotherapy for non-small cell lung cancer. <i>Lancet</i> , 2017, 389, 1394-1395.	6.3	2
88	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	3.4	224
89	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	1.4	15
90	Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer. <i>Neuro-Oncology</i> , 2017, 19, 1015-1016.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.3	51
92	Non-tunneled versus tunneled dialysis catheters for acute kidney injury requiring renal replacement therapy: a prospective cohort study. <i>BMC Nephrology</i> , 2017, 18, 351.	0.8	26
93	Radiographic Prediction of Meningioma Grade and Genomic Profile. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	1
94	Radiographic prediction of meningioma grade by semantic and radiomic features. <i>PLoS ONE</i> , 2017, 12, e0187908.	1.1	109
95	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. <i>Journal of Neuro-Oncology</i> , 2016, 129, 389-393.	1.4	7
96	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e7-233.e15.	0.8	34
97	Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016, 122, 78-83.	2.0	41
98	Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". <i>New England Journal of Medicine</i> , 2016, 375, 196-198.	13.9	138
99	Genomic landscape of intracranial meningiomas. <i>Journal of Neurosurgery</i> , 2016, 125, 525-535.	0.9	104
100	Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 1241-1247.	0.5	68
101	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. <i>World Neurosurgery</i> , 2016, 85, 96-105.	0.7	14
102	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. <i>Neuro-Oncology</i> , 2016, 18, 649-655.	0.6	221
103	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 61-68.	2.3	72
104	Extent of resection and overall survival for patients with atypical and malignant meningioma. <i>Cancer</i> , 2015, 121, 4376-4381.	2.0	144
105	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.4	46
106	Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. <i>Journal of Neuro-Oncology</i> , 2015, 124, 291-297.	1.4	24
107	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv054-djv054.	3.0	63
108	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	0.6	40

#	ARTICLE	IF	CITATIONS
109	Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. Journal of Neuro-Oncology, 2015, 124, 429-437.	1.4	13
110	Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer, 2014, 120, 1532-1539.	2.0	204
111	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112
112	Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer. Journal of Oncology Practice, 2014, 10, 107-112.	2.5	9
113	Cytoreductive nephrectomy in patients with metastatic non-clear cell renal cell carcinoma (<sc>RCC</sc>). BJU International, 2014, 113, E67-74.	1.3	62
114	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	0.6	80
115	Marital Status and Survival in Patients With Cancer. Journal of Clinical Oncology, 2013, 31, 3869-3876.	0.8	789
116	Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1364-1372.	2.3	15
117	Should all colorectal cancer patients over age 60 be screened for prostate cancer?. Oncology, 2013, 27, 1032-8.	0.4	0
118	A tale of two tumors: pediatric and adult medulloblastoma. Oncology, 2012, 26, 1095-7.	0.4	0